RedHill Biopharma announced that in vitro studies confirm RHB-204's ability to kill Mycobacterium avium subspecies paratuberculosis (MAP), showing comparable efficacy to their existing drug RHB-104. This supports RHB-204's potential as a safer, optimized treatment for MAP-related Crohn's disease, following RHB-104's positive Phase 3 results demonstrating a 64% improvement over standard care. The studies, led by top microbiology experts, also suggest RHB-204 may reduce toxicity and side effects due to lower doses of active ingredients. RedHill plans to advance RHB-204 into Phase 2 trials targeting MAP-positive Crohn's patients, aiming to address both disease cause and symptoms with an oral therapy.
The news on RedHill's RHB-204 for Crohn's disease provides context for readers interested in health-sector stocks. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 02, 2026 18:12 WIB: out of 150 priced US health stocks, 70 rose and 54 fell. Among notable movers, HRTX rose 4.43% to USD 0.29 with a typical hold time of 38 days, contrasting with ELAN which fell 3.82% to USD 22.18 and a shorter hold time of 24 days. XRAY also gained 3.78% to USD 9.89, with the longest hold time of 74 days among these.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
